Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

NCT06623136 is registered in ClinicalTrials.gov with Elpiscience (Suzhou) Biopharma, Ltd. as lead sponsor.

NCT NCT06623136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06623136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Lead sponsor
Elpiscience (Suzhou) Biopharma, Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2025
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer